Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Ali T. Taher, MD PhD, Raffaella Origa, Silverio Perrotta, Alexandra Kouraklis, Giovan Battista Ruffo, Antonis Kattamis, MD, Ai-Sim Goh, Annelore Cortoos, Vicky Huang, Marine Weill, Raquel Merino Herranz, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD

Blood (2016) 128 (22): 1285.

https://doi.org/10.1182/blood.V128.22.1285.1285

Published: 2016

Journal Articles

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Blood (2016) 128 (22): 850.

https://doi.org/10.1182/blood.V128.22.850.850

Published: 2016

Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD

Blood (2016) 128 (22): 852.

https://doi.org/10.1182/blood.V128.22.852.852

Published: 2016

Journal Articles

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Ali Amid, MD, Rebecca Leroux, BScN, Manuela Merelles-Pulcini, MSc, Saeed Yassobi, MD, Antoine N Saliba, MD, Richard Ward, MSc, MRCP, FRCPath, Mehran Karimi, MD, Ali T. Taher, MD PhD, Robert J Klaassen, MD, Melanie Kirby-Allen, MD

Blood (2016) 128 (22): 3633.

https://doi.org/10.1182/blood.V128.22.3633.3633

Published: 2016

Journal Articles

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

John B Porter, MD, Ali T Taher, MD PhD, Yesim Aydinok, MD, Amal El-Beshlawy, MD/Professor, Mohsen El-Alfy, MD, Ali El-Ali, MD, Subhashish Chakravarty, PhD, M Domenica Cappellini, MD

Blood (2014) 124 (21): 1366.

https://doi.org/10.1182/blood.V124.21.1366.1366

Published: 2014

NARROW

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

Email alerts

ASH Publications

American Society of Hematology

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Factors Impacting Quality of Life in Thalassemia Patients; Results from the Intercontinenthal Collaborative Study

Multivariate Analysis Evaluating Potential Predictors of Cardiac T2* Where Cardiac Magnetic Resonance Imaging (CMR) Availability Is Limited

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only